Related references
Note: Only part of the references are listed.HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Per Anderson et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer
Maria Antonia Garrido et al.
CANCERS (2021)
Targeting loss of heterozygosity for cancer-specific immunotherapy
Michael S. Hwang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes
Hernani Gil-Julio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response
Meagan Montesion et al.
CANCER DISCOVERY (2021)
Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
Nicolas Huyghe et al.
GASTROENTEROLOGY REPORT (2020)
Interferons α and β in cancer: therapeutic opportunities from new insights
Ernest C. Borden
NATURE REVIEWS DRUG DISCOVERY (2019)
Cancer immune escape: MHC expression in primary tumours versus metastases
Federico Garrido et al.
IMMUNOLOGY (2019)
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
Natalia Aptsiauri et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Rejection versus escape: the tumor MHC dilemma
Federico Garrido et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration
Francisco Perea et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Kazuyoshi Takeda et al.
NATURE COMMUNICATIONS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture
Federico Garrido et al.
VACCINES (2017)
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
Rikke Andersen et al.
CLINICAL CANCER RESEARCH (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
NLRC5/MHC class I transactivator is a target for immune evasion in cancer
Sayuri Yoshihama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition
A. B. del Campo et al.
CANCER GENE THERAPY (2014)
T Lymphocytes Restrain Spontaneous Metastases in Permanent Dormancy
Irene Romero et al.
CANCER RESEARCH (2014)
MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Trevor E. Angell et al.
CLINICAL CANCER RESEARCH (2014)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Ana B. del Campo et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
A novel preclinical murine model of immune-mediated metastatic dormancy
Irene Romero et al.
ONCOIMMUNOLOGY (2014)
Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer
Hannah V. Siddle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells
Irene Romero et al.
JOURNAL OF PATHOLOGY (2012)
Targeting HLA class I expression to increase tumor immunogenicity
A. B. del Campo et al.
TISSUE ANTIGENS (2012)
Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells
Rafael Carretero et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible hard lesions
Federico Garrido et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Immune evasion of microsatellite unstable colorectal cancers
Matthias Kloor et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue
P. Saenz-Lopez et al.
TISSUE ANTIGENS (2010)
Efficient Recovery of HLA Class I Expression in Human Tumor Cells After Beta2-Microglobulin Gene Transfer Using Adenoviral Vector: Implications for Cancer Immunotherapy
A. B. del Campo et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2009)
Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations
Natalia Aptsiauri et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
Rafael Carretero et al.
IMMUNOGENETICS (2008)
HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer
Eiki Kikuchi et al.
CANCER SCIENCE (2007)
Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy
Rosa Mendez et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components
A Garcia-Lora et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Analysis of HLA expression in human tumor tissues
T Cabrera et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
HLA class I antigen loss, tumor immune escape and immune selection
M Campoli et al.
VACCINE (2002)
Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas:: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21
I Maleno et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
HLA expression in uveal melanoma: There is no rule without some exception
MJ Jager et al.
HUMAN IMMUNOLOGY (2002)
Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer
LA Koopman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
